Sign in
Active, not recruitingNo phase

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects

Key facts

Who runs it
University Medical Center Groningen
Where
Netherlands3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
939 people enrolled
Started
Jul 2014
Ended
Apr 2026
Type of study
Observational, 2 groups
Treatments tested
  • Vena punction
Record updated
15 September 2025

Who can take part

Age
18 years to 75 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who cannot take part

  • Mental disorder (no informed consent available)
  • Presence of active malignant disease
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:

Other criteria

  • All participating patients have to meet the following criteria:
  • Alive
  • TC diagnosis between 01-01-1976 to 31-12-2007
  • TC treatment center: UMCG, NKI/AVL, Erasmus MC, UMCN, LUMC
  • Younger than 50 years of age at TC diagnosis
  • Written informed consent; Cases have to fulfill, beside the aforementioned criteria, the following criteria:
  • Diagnosed with either myocardial infarction (MI), proven coronary artery disease (CAD) (CTCAE-4 grade 2 or higher) or congestive heart failure (CHF) (CTCAE-4 grade 2 or higher)
  • No medical history of CVD before diagnosis of TC; In order to be eligible to participate in the cardiometabolic risk inventory study (and to be invited to a study assessment), a subject must meet, next to the criteria mentioned in "1)", the following inclusion criteria:
  • Younger than 40 years of age at TC diagnosis
  • Younger than 75 years of age at moment of inclusion

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late 1970s. Given the good prognosis of TC nowadays, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Current literature suggests that TC treatment, and specifically exposure to platinum agents, is associated with increased risk of cardiovascular morbidity and mortality. The precise role of treatment components like platinum in the pathogenesis of cardiometabolic changes and cardiovascular disease (CVD) warrants further investigation, since it is not known if CVD develops through direct platinum-induced damage of the vascular wall or by mediation through development of cardiometabolic riskfactors. The aim of this study is to identify risk factors for development for CVD after treatment for TC. A more profound insight into pathophysiologic mechanisms and identification of risk factors for CVDs is needed to facilitate development of preventive strategies and to optimize survivorship care.

The 2 groups in the trial

  • Cases

    Patients who developed cardiovascular disease after testicular cancer treatment

    Treatment: Vena punction

  • Subcohort members

    A random selection out of the total cohort of testicular cancer patients per participating hospital

    Treatment: Vena punction

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors
Publications
Record updated
15 September 2025